1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Express Scripts Realignment Identifies Non-Core Businesses

 
• By Cathy Kelly

Express Scripts is “looking at strategic alternatives” for some of its non-core businesses, which include international ventures, UBC and PolyMedica.

Express Scripts Holding Co.s’ recent realignment identifies as non-core businesses the international ventures it has developed in-house and those acquired with Medco Health Solutions Inc., as well as Medco’s United BioSource Corporation and PolyMedica Corp. units, Chief Financial Officer Jeff Hall said during the pharmacy benefit manager’s second quarter financial call Aug. 8.

The company has reorganized its business into two reporting segments, core businesses and “other” businesses, since the merger with rival...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

US Strategic Reserve Bulking Up: New Order Focuses On API Stockpile

 
• By Laura Helbling

The White House is directing the Health and Human Services Department to replenish stockpiles of active pharmaceutical ingredients for “especially critical” medicines.

Medicare Part D Plans Turn to Coinsurance, Higher Deductibles Amid IRA Changes

 
• By Tim Casey

Newly implemented IRA provisions may not necessarily lower drug costs for those enrolled in Medicare Part D plans, according to research by the USC Schaeffer Center for Health Policy and Economics.

Selective Safety Data Collection In Clinical Trials: Adoption Lags Despite Benefits, US FDA Says

 
• By Manas Mishra

Lack of awareness is limiting use of guidelines that simplify safety reporting for some late-stage trials, FDA says, while also highlighting wins. Boehringer experienced mixed results, while Novartis, Lilly, and Merck were more successful, and Roche should have probably tried, white paper suggests.